唯捷創芯(688153.SH):公司自主研發的L-PAMiD產品實現了批量出貨 預計今年下半年能夠實現大規模出貨
格隆匯9月12日丨唯捷創芯(688153.SH)接受特定對象調研 時表示,今年上半年,公司自主研發的L-PAMiD產品實現了批量出貨,成為國內率先實現向頭部品牌客户批量銷售該產品的企業,預計今年下半年能夠實現大規模出貨,新一代L-PAMiD產品也正在研發和準備中。L-PAMiD開發既需要設計端的積累,也需要生產、運營端的穩定能力。公司會繼續深度開發,提升L-PAMiD產品性能,為未來更高階模塊的發展打好基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.